Heron Therapeutics traded at $3.70 this Friday May 20th, increasing $0.13 or 3.68 percent since the previous trading session. Looking back, over the last four weeks, Heron Therapeutics gained 32.58 percent. Over the last 12 months, its price fell by 74.03 percent. Looking ahead, we forecast Heron Therapeutics to be priced at 3.61 by the end of this quarter and at 3.35 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
3.70
Daily Change
3.68%
Yearly
-74.03%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 5,483.00 13.00 0.24% -20.44%
ALKERMES 30.39 0.91 3.09% 38.64%
Alnylam Pharmaceuticals 132.06 2.70 2.09% -5.74%
Amarin 1.43 -0.02 -1.04% -68.75%
Anika Therapeutics 21.42 -0.47 -2.15% -51.38%
ANI Pharmaceuticals 30.59 0.67 2.24% -13.54%
Arrowhead Research 35.91 0.76 2.16% -51.95%
Emergent BioSolutions 34.36 2.67 8.43% -41.41%
Endo International 0.46 -0.11 -19.56% -91.69%
Esperion Therapeutics 6.36 0.18 2.91% -68.95%
GlaxoSmithKline 1,757.20 25.60 1.48% 29.68%
Heron Therapeutics 3.70 0.13 3.68% -74.03%
Immunogen 3.67 0.14 3.82% -42.82%
Insmed 19.91 0.34 1.74% -24.21%
Jazz Pharmaceuticals 150.07 0.54 0.36% -15.97%
Ligand Pharmaceuticals 84.06 1.32 1.60% -31.96%
Merck & Co 93.58 1.49 1.62% 18.19%
Neurocrine Biosciences 85.94 0.57 0.67% -8.93%
Nektar Therapeutics 4.00 0.09 2.30% -77.96%
Omeros 2.89 0.01 0.35% -80.91%
Pacira 63.72 0.68 1.08% -3.91%
Ultragenyx Pharmaceutical 47.05 0.05 0.10% -57.94%
Regeneron Pharmaceuticals 661.65 4.50 0.68% 30.58%
Roche Holding 318.20 1.30 0.41% 3.31%
Sangamo BioSciences 4.10 0.10 2.50% -62.52%
Surmodics 36.08 -0.03 -0.08% -32.89%
Teva Pharmaceutical Industries 8.48 0.17 2.05% -21.26%
Veracyte 17.76 0.29 1.66% -52.17%
Vertex Pharmaceuticals 258.84 3.39 1.33% 21.28%

Indexes Price Day Year
USND 11355 -33.88 -0.30% -15.71%
US2000 1773 -2.96 -0.17% -19.95%

Heron Therapeutics
Heron Therapeutics, Inc. is a biotechnology company. The Company is focused in developing pharmacological agents for patients suffering from pain or cancer. Its oncology care product portfolio consists of SUSTOL and CINVANTI. Its SUSTOL (granisetron) is an extended-release, injectable used in the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Its CINVANTI, in combination with other antiemetic agents is used in the prevention of acute and delayed nausea and vomiting associated with emetogenic cancer chemotherapy (HEC). The Company's acute care product portfolio consist of ZYNRELEF (HTX-011) HTX-034, and HTX-019. The ZYNRELEF (HTX-011) is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam.